A novel [99mTc≡N]2+ complex of metronidazole xanthate as a potential agent for targeting hypoxia

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 14, 2005, Pages 3398-3401

  Mallia, Madhava B ^a   Mathur, Anupam ^b   Subramanian, Suresh ^a   Banerjee, Sharmila ^a   Sarma, H D ^a   Venkatesh, Meera ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

^b Medical and Biological Products Program   (India)

Author keywords

Hypoxia imaging; Metronidazole xanthate; Technetium nitrido complex

Indexed keywords

METRONIDAZOLE; TECHNETIUM 99M; XANTHIC ACID DERIVATIVE; BRU 59 21; BRU 59-21; DIAGNOSTIC AGENT; DRUG DERIVATIVE; IMIDAZOLE DERIVATIVE; LIGAND; NITROIMIDAZOLE DERIVATIVE; OXO[3,3,9,9 TETRAMETHYL 1 (2 NITRO 1H IMIDAZOL 1 YL) 4,8 DIAZAUNDECANE 2,10 DIONEDIOXIMATO]TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CHELATION; CONTROLLED STUDY; FIBROSARCOMA; GENE TARGETING; HYPOXIA; LIGAND BINDING; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; ANIMAL; ANOXIA; CANCER TRANSPLANTATION; CHEMICAL STRUCTURE; COMPARATIVE STUDY; EXPERIMENTAL NEOPLASM; SCINTISCANNING; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TIME; TISSUE DISTRIBUTION;

ANIMALS; ANOXIA; IMIDAZOLES; LIGANDS; METRONIDAZOLE; MICE; MOLECULAR STRUCTURE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NITROIMIDAZOLES; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 20644433099     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.05.030     Document Type: Article

References (15)

1. A. Nunn, K. Linder, and H.W. Strauss Eur. J. Nucl. Med. 22 1995 265
2. L.H. Gary, A.D. Conger, M. Ebert, S. Hornsey, and O.C.A. Scott Br. J. Radiol. 26 1953 638
3. J.E. Moulder, and S. Rockwell Cancer Metastasis Rev. 5 1987 313
4. J.R. Ballinger Semin. Nucl. Med. 31 2001 321
5. J.M. Brown Int. J. Radiat. Oncol. Biol. Phys. 16 1989 987
6. J.D. Chapman N. Engl. J. Med. 301 1979 1429
7. T. Das, S. Banerjee, Grace Samuel, H.D. Sarma, Aruna Korde, Meera Venkatesh, and M.R.A. Pillai Nucl. Med. Biol. 30 2003 127
8. J. Baldas, and J. Bonnyman Int. J. Appl. Radiat. Isot. 36 1985 133
9. S. Abram, A. Abram, H. Spies, and R. Munze J. Radioanal. Nucl. Chem. Art. 102 1986 309
10. R. Pasqualini, A. Duatti, E. Bellande, V. Comazzi, V. Brucato, D. Hoffschir, D. Fagret, and M. Comet J. Nucl. Med. 35 1994 334
11. R. Pasqualini, and A. Duatti J. Chem. Soc., Chem. Commun. 18 1992 1354
12. Kit-vial compostion: succinic acid dihydrazide (SDH) (5 mg), tin(II)chloride (0.1 mg), 1,2-diaminopropane-N,N,N′,N′-tetraacetic acid (PDTA) (5 mg), sodium dihydrogen phosphate anhyd (0.5 mg), disodium hydrogen phosphate anhyd (5.8 mg)
13. D. Ma, F. Lu, T. Oversheet, D.E. Milenic, and M.W. Brechtiel Nucl. Med. Biol. 29 2002 91
14. J.R. Ballinger, J.W.M. Kee, and A.M. Rauth J. Nucl. Med. 37 1996 1023
15. T. Melo, J. Duncan, J.R. Ballinger, and A.M. Rauth J. Nucl. Med. 41 2000 169